The silent hormone: How adrenal tumors quietly raise cardiovascular risk over time
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A major new study, published in The Lancet Diabetes & Endocrinology, has shown that cortisol levels in patients with adrenal tumors are far less stable than previously assumed. The study also found that those in whom cortisol remains persistently elevated carry a significantly greater risk of worsening high blood pressure and a heavier overall cardiometabolic burden.
Cortisol, often referred to as the "stress hormone," is a steroid hormone produced by the adrenal glands that acts as a master regulator of metabolism, blood pressure and immune function. When benign tumors form on the adrenal glands (found incidentally in 3%–7% of adults), they can cause the body to produce cortisol independently of normal regulatory controls, a condition known as mild autonomous cortisol secretion (MACS).
Until now, it was unclear how cortisol levels in these patients change over time, and what that means for their long-term health.
Tracking cortisol over time
The study of more than 2,500 patients was conducted by researchers from 25 specialist adrenal centers across 14 countries as part of the European Network for the Study of Adrenal Tumors (ENSAT). It is the largest study of its kind to examine how cortisol patterns evolve over time in patients with benign adrenal tumors and what this means for cardiovascular outcomes.
The study followed 2,525 patients with benign adrenal tumors for an average of nearly seven years. Each patient underwent repeated hormonal testing using the 1 mg overnight dexamethasone suppression test, the standard clinical test used to assess whether the adrenal gland is overproducing cortisol autonomously.
Patients were classified based on whether their cortisol levels remained normal, remained elevated (persistent MACS), or changed between categories over time.
Persistent elevation carried the highest risk
The researchers found that cortisol secretion status changed in 22% of patients, far more frequently than previously recognized, with most changes occurring within the first three years after diagnosis. These findings challenge the assumption that a single hormonal test is sufficient to characterize a patient's long-term cortisol profile.
Patients with persistent MACS had the greatest overall cardiovascular burden and faced a 34% higher rate of worsening high blood pressure than those with persistently normal cortisol.
Over 10 years, patients with persistent MACS lost an average of two years of well-controlled hypertension-free time compared with those whose cortisol remained normal—a clinically meaningful difference in long-term blood pressure control.
Cardiometabolic burden refers to the combined impact of interrelated metabolic and cardiovascular risk factors (including obesity, high blood pressure, type 2 diabetes and high cholesterol) on overall health, predisposing serious, chronic diseases such as heart failure, heart attack and stroke.
Implications for follow-up and treatment
The study identified patients with persistently abnormal cortisol levels (persistent MACS) as a clinically important, higher-risk group who may benefit from closer monitoring and more proactive management of modifiable risk factors—including blood pressure, cholesterol, weight and smoking.
The results are also consistent with randomized trial data, also published in The Lancet Diabetes & Endocrinology, showing that surgery to remove the adrenal tumor can improve blood pressure control in MACS.
Professor Alessandro Prete, clinical associate professor of endocrinology at the University of Birmingham, co-lead for the NIHR Birmingham Biomedical Research Center's Women's Metabolic Health theme, and corresponding author and senior investigator of the study, said, "For many years, the assumption has been that a single hormone test at adrenal tumor diagnosis tells us everything we need to know about a patient's cortisol status.
"This study shows that it is simply not the case—cortisol levels change over time in a substantial proportion of patients, and those in whom they remain persistently elevated are at a meaningfully higher risk of developing uncontrolled blood pressure.
"These findings should prompt us to think more carefully about which patients need closer follow-up, and whether active treatment to reduce cortisol excess—including surgery in selected cases—could protect their long-term cardiovascular health."
Questions for future testing guidance
The study also provides important new evidence to inform the ongoing debate around whether, and how often, cortisol testing should be repeated in patients with benign adrenal tumors.
Current guidelines recommend repeating the test only in specific clinical circumstances; the authors of the study are calling for prospective studies to determine whether repeated hormonal assessment contributes meaningfully to risk stratification beyond established cardiovascular risk factors.
Publication details
Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: an ENSAT retrospective cohort study, The Lancet Diabetes & Endocrinology (2026). DOI: 10.1016/S2213-8587(26)00098-7
Journal information: The Lancet Diabetes & Endocrinology
Clinical categories
EndocrinologyCardiologyCommon illnesses & Prevention Provided by University of Birmingham Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: The silent hormone: How adrenal tumors quietly raise cardiovascular risk over time (2026, July 7) retrieved 7 July 2026 from https://medicalxpress.com/news/2026-07-silent-hormone-adrenal-tumors-quietly.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.